Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Abstract

Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab

“…The model is statistically robust and respects pertinent quality criteria proposed for prognostic scores, such as a well-defined cohort of patients, a comprehensive evaluation of all well-established prognostic variables, reliable outcome measures, few patients lost to follow-up, and data available for the vast majority (Maltoni et al , 2005). Some imbalances are seen regarding clinical features, CT schedules, HER2 testing, and trastuzumab therapy, as well as survival between the derivation and validation subsets as a reflection of recent epidemiological trends and the changes in patient interventions over time (Jiménez-Fonseca et al , 2017). Moreover, as it usually happens in other similar registries, there were some biochemical variables in the prospective series with a small proportion of missing data: alkaline phosphatase (3.58%), lactate dehydrogenase (14.74%), bilirubin (0.60%), albumin (8.76%) and carcinoembryonic antigen (13.34%).…”

“…Descriptions of the design, data collection, quality and eligibility criteria have been previously reported (Carmona-Bayonas et al , 2016; Jiménez-Fonseca et al , 2017). Briefly, patients eligible for inclusion were adults (age ⩾18 years) diagnosed with pathologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the distal oesophagus, GEJ, and stomach who received at least one cycle of polychemotherapy using two or more drugs as first-line treatment.…”

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

“…The study design, characteristics, method, and data quality criteria have been extensively reported previously [3,4]. Briefly, the eligibility criteria include adult patients (C 18 years) with histologically confirmed, unresectable or metastatic gastric, gastroesophageal junction (GEJ), or distal esophageal adenocarcinoma who received first-line chemotherapy.…”

“…However, this pathway is actived in only some 20% of the cases [2,3]. There are several treatment options for the remaining tumors (HER2 negative) that generally combine two or three cytostatics [4], with objective response rates of 35-45% and median overall survival (OS) rarely exceeding 12 months [5].…”

Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH

“…In 2010 after the results of the ToGA trial (11) evaluating Trastuzumab ® in metastatic overexpressing (3+ HER2) gastric and GEJ cancers, the US Food and Drug Administration (FDA) approved the drug in combination with cisplatin and capecitabine or 5-fluorouracil for the treatment of patients with HER2-overexpressing advanced stage metastatic gastric or GEJ adenocarcinoma (12). However, metastatic gastric cancer has already a poor prognosis and the use of targeted therapies such as Trastuzumab ® may also benefit patients with non-metastatic/ early stage HER2 positive adenocarcinomas (3,14).…”